Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe.

[1]  A. Croft,et al.  WITHDRAWN: Drugs for preventing malaria in travellers. , 2015, The Cochrane database of systematic reviews.

[2]  P. Schlagenhauf,et al.  Malaria chemoprophylaxis regimens: a descriptive drug utilization study. , 2014, Travel medicine and infectious disease.

[3]  A. Janowsky,et al.  Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro , 2014, Psychopharmacology.

[4]  F. Gobbi,et al.  Mefloquine restrictions, anti-malarial drug safety and the new Italian recommendations for malaria prophylaxis. , 2014, Travel medicine and infectious disease.

[5]  P. Schlagenhauf,et al.  Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders. , 2013, Travel medicine and infectious disease.

[6]  G. Pluschke,et al.  Cysteine-Rich Protective Antigen (CyRPA) as promising blood-stage candidate protein for inclusion in a malaria subunit vaccine , 2012, Malaria Journal.

[7]  Cho Naing,et al.  Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malaria , 2012, Drug, healthcare and patient safety.

[8]  P. Schlagenhauf,et al.  Standby emergency treatment of malaria in travelers: experience to date and new developments , 2012, Expert review of anti-infective therapy.

[9]  Remington Nevin.  Limbic encephalopathy and central vestibulopathy caused by mefloquine: a case report. , 2012, Travel medicine and infectious disease.

[10]  É. Caumes,et al.  Malaria update 2011 , 2011 .

[11]  A. Croft,et al.  Drugs for preventing malaria in travellers. , 2009, The Cochrane database of systematic reviews.

[12]  S. Toovey.  Mefloquine neurotoxicity: a literature review. , 2009, Travel medicine and infectious disease.

[13]  Remington Nevin,et al.  Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan , 2008, Malaria Journal.

[14]  B. Stricker,et al.  Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. , 2004, British journal of clinical pharmacology.

[15]  B. Krebs,et al.  Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study , 2003, BMJ : British Medical Journal.